P-Toluenesulfonamide

Summary

P-Toluenesulfonamide (CHEMBL574) is a phase-3 clinical-stage small molecule (ATC L01XX83); indicated across 3 conditions including non-small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01XX83
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 171.22 Da · C7H9NO2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL574
Name	P-Toluenesulfonamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6269
ChEBI	CHEBI:34435
ATC	L01XX83
Molecular formula	C7H9NO2S
Molecular weight	171.22
InChIKey	LMYRWZFENFIFIT-UHFFFAOYSA-N

SMILES: CC1=CC=C(C=C1)S(=O)(=O)N

IUPAC name: 4-methylbenzenesulfonamide

ChEBI definition: A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.

Also known as: NSC-9908, P-methylbenzenesulfonamide, P-toluenesulfonamide, P-toluenesulfonylamide, P-tosylamide, Para-toluenesulfonamide, Paratoulene sulfonamide, Toluenesulfonamide, p-, SID49675005, SID75262, SID17388752

Patent coverage: 10,151 distinct patent families (25,576 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 25,575 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 2, Carbonic anhydrase 7, Carbonic anhydrase 1, Carbonic anhydrase 3, Carbonic anhydrase 6, Carbonic anhydrase 12, Carbonic anhydrase 9, Carbonic anhydrase 5B, mitochondrial, Carbonic anhydrase.

Bioactivity

ChEMBL activities: 58 potent at pChembl ≥ 5 of 88 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA2	9.89	Kd	0.13	nM	CHEMBL_ACT_18110642
CA12	8.74	Ki	1.8	nM	CHEMBL_ACT_1436066
P00921	7.24	Ki	57.54	nM	CHEMBL_ACT_5131126
CA7	7.06	Ki	88	nM	CHEMBL_ACT_1423341
CA2	6.5	Ki	320	nM	CHEMBL_ACT_10946370
CA2	6.5	Ki	320	nM	CHEMBL_ACT_12656007
CA2	6.5	Ki	320	nM	CHEMBL_ACT_12667901
CA2	6.5	Ki	320	nM	CHEMBL_ACT_13866404
CA2	6.5	Ki	320	nM	CHEMBL_ACT_1423340
CA2	6.5	Ki	320	nM	CHEMBL_ACT_1436065
CA2	6.5	Ki	320	nM	CHEMBL_ACT_14661433
CA2	6.5	Ki	320	nM	CHEMBL_ACT_15108386
CA2	6.5	Ki	320	nM	CHEMBL_ACT_15143332
CA2	6.5	Ki	320	nM	CHEMBL_ACT_15169416
CA2	6.5	Ki	320	nM	CHEMBL_ACT_15177739
CA2	6.5	Ki	320	nM	CHEMBL_ACT_15674538
CA2	6.5	Ki	320	nM	CHEMBL_ACT_16415149
CA2	6.5	Ki	320	nM	CHEMBL_ACT_16451195
CA2	6.5	Ki	320	nM	CHEMBL_ACT_16478477
CA2	6.5	Ki	320	nM	CHEMBL_ACT_16519947
CA2	6.5	Ki	320	nM	CHEMBL_ACT_16532812
CA2	6.5	Ki	320	nM	CHEMBL_ACT_1655198
CA2	6.5	Ki	320	nM	CHEMBL_ACT_1692925
CA2	6.5	Ki	320	nM	CHEMBL_ACT_1708321
CA2	6.5	Ki	320	nM	CHEMBL_ACT_17997747
CA2	6.5	Ki	320	nM	CHEMBL_ACT_1804117
CA2	6.5	Ki	320	nM	CHEMBL_ACT_18160087
CA2	6.5	Ki	320	nM	CHEMBL_ACT_19413151
CA2	6.5	Ki	320	nM	CHEMBL_ACT_2421882
CA2	6.5	Ki	320	nM	CHEMBL_ACT_2494404

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
neoplasm	3	MONDO:0005070	EFO:0000616
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03448146	PHASE3	COMPLETED	A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction
NCT03447951	PHASE2	UNKNOWN	A Study of PTS100 in Primary HCC Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).